Investigational drug · Phase 3
Empasiprubart
Also called: ARGX-117
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multifocal Motor Neuropathy (MMN), Chronic Inflammatory Demyelinating Polyneuropathy, CIDP.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
9 still active
All registered trials
12
Any phase or sponsor naming "Empasiprubart"
First trial start
2023
Jan 18, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Empasiprubart", any sponsor or status.
Conditions studied
As listed on its trial records.
- Multifocal Motor Neuropathy (MMN)
- Chronic Inflammatory Demyelinating Polyneuropathy
- CIDP
- AChR-Ab Seropositive Generalized Myasthenia Gravis
- gMG
- Delayed Graft Function
- MMN
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
- Myasthenia Gravis
Approved drugs for the same conditions: Myasthenia gravis · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Empasiprubart" as an intervention, largest first.
- A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPPivotal-lookingRecruiting
argenxargenx (ARGX)
NCT06920004 · 218 participants (planned) · Start Aug 22, 2025 · Primary completion Sep 2027
Drug: empasiprubart; IVIg · For: Chronic Inflammatory Demyelinating Polyneuropathy; CIDP; CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Sites: Birmingham, Alabama; Tucson, Arizona; Rancho Mirage, California · 109 sites in all
- A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDPPivotal-lookingRecruiting
argenxargenx (ARGX)
NCT07091630 · 160 participants (planned) · Start Sep 16, 2025 · Primary completion Oct 7, 2027
Drug: Empasiprubart IV · For: Chronic Inflammatory Demyelinating Polyneuropathy; CIDP; Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Sites: Birmingham, Alabama; Tucson, Arizona; Rancho Mirage, California · 95 sites in all
- A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor NeuropathyPivotal-lookingActive, not recruiting
argenxargenx (ARGX)
NCT06742190 · 154 participants · Start Dec 18, 2024 · Primary completion Sep 2026
Drug: Empasiprubart; IVIG (Intravenous Immunoglobulin) · For: Multifocal Motor Neuropathy (MMN); MMN
Sites: Scottsdale, Arizona; Pomona, California; Rancho Mirage, California · 109 sites in all
- A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult ParticipantsPivotal-lookingRecruiting
argenxargenx (ARGX)
NCT07612020 · 130 participants (planned) · Start Mar 16, 2026 · Primary completion Mar 2027
Drug: empasiprubart SC AI; empasiprubart IV · For: Healthy Volunteers
Sites: Mount Royal, Canada
argenxargenx (ARGX)
NCT07294170 · 70 participants (planned) · Start Dec 19, 2025 · Primary completion Mar 7, 2028
Drug: Efgartigimod IV; Empasiprubart IV and 1 more · For: Myasthenia Gravis; MG; gMG and 3 more
Sites: Carlsbad, California; Miami, Florida; Tampa, Florida · 37 sites in all
argenxargenx (ARGX)
NCT07284420 · 70 participants (planned) · Start Dec 19, 2025 · Primary completion Mar 7, 2028
Drug: Efgartigimod IV; Empasiprubart IV · For: AChR-Ab Seropositive Generalized Myasthenia Gravis; Myasthenia Gravis; MG and 3 more
Sites: Carlsbad, California; Miami, Florida; Tampa, Florida · 33 sites in all
- A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré SyndromeNot yet recruiting
argenxargenx (ARGX)
NCT07821762 · 63 participants (planned) · Start Dec 2026 · Primary completion Jan 2028
Drug: Empasiprubart IV; Intravenous immunoglobulin (IVIg) · For: Guillain-Barré Syndrome (GBS)
argenxargenx (ARGX)
NCT07610564 · 60 participants (planned) · Start Jul 27, 2026 · Primary completion Feb 1, 2028
Drug: Empasiprubart IV · For: Multifocal Motor Neuropathy (MMN)
Sites: New Haven, Connecticut; Tbilisi, Georgia · 5 sites in all
argenxargenx (ARGX)
NCT07673627 · 40 participants (planned) · Start Jul 10, 2026 · Primary completion Oct 2027
Drug: Empasiprubart IV · For: AChR-Ab Seropositive Generalized Myasthenia Gravis; Myasthenia Gravis (MG); MG - Myasthenia Gravis and 1 more
Sites: Carlsbad, California; Miami, Florida; Tampa, Florida · 19 sites in all
argenxargenx (ARGX)
NCT07782775 · 32 participants · Start Jun 19, 2026 · Primary completion Sep 23, 2026
Drug: Efgartigimod PH20 SC via PFS; Efgartigimod PH20 SC via AI · For: Healthy Volunteer; Healthy Adult Participants
Sites: Montreal, Canada
Newest research
PubMed records naming it or its code names, newest first.
- Structure-function analysis of empasiprubart, a calcium- and pH-dependent clinical phase complement C2 blocking antibody.
Bracke L, Gytz Olesen H, Pannecoucke E, et al. · MAbs 2026
- Development of an anti-rat complement C2 antibody that improves renal outcome in a rat kidney transplant model.
Bracke L, Delaere J, Haspeslagh E, et al. · Front Immunol 2025
- Immunotherapies in chronic immune-mediated neuropathies.
Briani C, Visentin A · Handb Clin Neurol 2026
- Randomized phase I trial outcomes show safe and sustainable inhibition of classical and lectin complement pathways by empasiprubart.
Van de Walle I, Bracke L, Olesen HG, et al. · Nat Commun 2025
- Complement inhibition prevents glial nodal membrane injury in a GM1 antibody-mediated mouse model.
Campbell CI, McGonigal R, Barrie JA, et al. · Brain Commun 2022
- Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy.
Budding K, Johansen LE, Van de Walle I, et al. · Neurol Neuroimmunol Neuroinflamm 2022
Also in development for Multifocal Motor Neuropathy (MMN)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from argenx.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.